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Denis Logunov and colleagues1 report their interim results from a phase 3 trial of the 
Sputnik V COVID-19 vaccine in The Lancet. The trial results show a consistent 
strong protective effect across all participant age groups. Also known as Gam-COVID-
 Vac, the vaccine uses a heterologous recombinant adenovirus approach using 
 adenovirus 26 (Ad26) and adenovirus 5 (Ad5) as vectors for the expression of the 
 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. The 
 use of two varying serotypes, which are given 21 days apart, is intended to overcome 
 any pre-existing adenovirus immunity in the population.2 Among the major COVID 
 vaccines in development to date, only Gam-COVID-Vac uses this approach; others, 
 such as the Oxford–AstraZeneca vaccine, use the same material for both doses. The 
 earlier vaccine for Ebola virus disease, also developed at Gamaleya National 
 Research Centre for Epidemiology and Microbiology (Moscow, Russia), was similar, 
 with Ad5 and vesicular stomatitis virus as the carrier viruses,3 and the general 
 principle of prime boost with two different vectors has been widely used 
 experimentally.4 
 The recombinant adenovirus route to protection is shared with the Oxford–
 AstraZeneca vaccine, which uses a chimpanzee adenovirus (ChAdOx),5 the Johnson 
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& Johnson vaccine that uses only Ad266 whose detailed results are expected soon, 
 and the CanSinoBIOBeijing Institute of Biotechnology Ad5-based vaccine whose 
 phase 3 trial began in September, 2020.7 The carrier viruses are modified and cannot 
 initiate a productive infection; they enter cells, express the spike protein, and then stop 
 (because they cannot continue the normal virus lifecycle), although a highsensitivity 
analysis also showed that a few Ad genes were expressed, albeit at a low level.8 The 
 vaccineinfected cells are eventually destroyed by the very immunity they are designed 
 to elicit. Recombinant adenoviruses have been used widely as vaccine vectors 
 because they can accommodate large genetic payloads and, although unable to 
 replicate, they trigger the innate immunity sensors sufficiently to ensure robust
 immune system engagement.9 Consequently, they do not need an adjuvant and can 
 provide immunity after just a single dose.4  Their physical robustness is thought 
to allow storage at temperatures around –18°C, which is feasible for many supply 
 chains. The downside of recombinant adenovirus-based vaccines is that large doses 
 are required, typically 10¹⁰ or 10¹¹ particles, which makes large demands on the 
 manufacturing and quantitation required for rollout on a global scale. What then of the 
 Sputnik V COVID-19 vaccine data published here? The earlier phase 1/2 data 
 published in September, 2020, showed promising safety results and gave an 
 indication that the immune response was at a level consistent with protection.10 
 Recipients generated robust antibody responses to the spike protein, which included 
 neutralising antibodies, the proportion of the total immunoglobulin that inhibits the virus 
 binding to its receptor. They also showed evidence of T-cell responses, consistent with 
 an immune response that should not quickly wane. The interim report of the phase 3 
 data1 now presented includes results for more than 20 000 participants, 75% of whom 
 were assigned to receive the vaccine, and the follow-up for adverse  events and 
 infection. With a planned study power of 85%, those recruited were aged 18 years and 
 older, were about 60% male, and were almost all white. Comorbidities, a known risk 
 for COVID-19 severity, were present in about a quarter of those who entered the trial. 
 62 (1·3%) of 4902 individuals in the placebo group and 16 (0·1%) of 14 964 
 participants in the vaccine group had confirmed SARS-CoV-2 infection from day 21 
 after first vaccine dose (the primary outcome). A time-resolved plot of the incidence 
 rate in the two groups showed that the immunity required to prevent disease arose 
 within 18 days of the first dose. That protection applied to all age groups, including 
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those older than 60 years, and the anecdotal case histories of those vaccinated but 
 infected suggest that the severity of disease decreases as immunity develops. Three 
 fatalities occurred in the vaccine group in individuals with extensive comorbidities, and 
 were deemed unrelated to the vaccine. No serious adverse events considered related 
 to the vaccine were recorded, but serious adverse events unrelated to the vaccine 
were reported in 45 participants from the vaccine group and 23 participants from the 
 placebo group. Vaccine efficacy, based on the numbers of confirmed COVID-19 cases 
 from 21 days after the first dose of vaccine, is reported as 91·6% (95% CI 85·6–95·2), 
and the suggested lessening of disease severity after one dose is particularly 
 encouraging for current dose sparing strategies. The development of the Sputnik V 
 vaccine has been criticised for unseemly haste, corner cutting, and an absence of 
 transparency.11 But the outcome reported here is clear and the scientific principle of 
vaccination is demonstrated, which means another vaccine can now join the fight to 
 reduce the incidence of COVID-19. 
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